Advanced search
Publication Cover
Expert Review of Medical Devices Volume 10, 2013 - Issue 4
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Treatment of coronary drug-eluting stent restenosis: a journey back to the future?

Lamin A King Deutsches Herzzentrum, Technische Universität, Munich, Germany and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
,
Adnan Kastrati Deutsches Herzzentrum, Technische Universität, Munich, Germany and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germanyy
&
Robert A Byrne Deutsches Herzzentrum, Technische Universität, Munich, Germany and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. [email protected]
Pages 423-427 | Published online: 09 Jan 2014

References

  • Byrne RA, Sarafoff N, Kastrati A, Schömig A. Drug-eluting stents in percutaneous coronary intervention: a benefit–risk assessment. Drug Saf. 32(9), 749–770 (2009).
  • Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 368(3), 254–265 (2013).
  • Bangalore S, Kumar S, Fusaro M et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125(23), 2873–2891 (2012).
  • Stefanini GG, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur. Heart J. 33(10), 1214–1222 (2012).
  • Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 56(23), 1897–1907 (2010).
  • Steinberg DH, Gaglia MA Jr, Pinto Slottow TL et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am. J. Cardiol. 103(4), 491–495 (2009).
  • Popma JJ, Leon MB, Moses JW et al.; SIRIUS Investigators. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110(25), 3773–3780 (2004).
  • Gonzalo N, Serruys PW, Okamura T et al. Optical coherence tomography patterns of stent restenosis. Am. Heart J. 158(2), 284–293 (2009).
  • Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol. 60(5), 473–489 (2012).
  • Kang SJ, Mintz GS, Park DW et al. Tissue characterization of in-stent neointima using intravascular ultrasound radiofrequency data analysis. Am. J. Cardiol. 106(11), 1561–1565 (2010).
  • Malle C, Tada T, Steigerwald K et al. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. Arterioscler. Thromb. Vasc. Biol. 33(6), 1376–1383 (2013).
  • Albiero R, Silber S, Di Mario C et al.; RESCUT Investigators. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J. Am. Coll. Cardiol. 43(6), 943–949 (2004).
  • Alfonso F, Augé JM, Zueco J et al.; RIBS Investigators. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J. Am. Coll. Cardiol. 46(5), 756–760 (2005).
  • Alfonso F, Pérez-Vizcayno MJ, Hernández R et al.; RIBS-II Investigators. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J. Am. Coll. Cardiol. 52(20), 1621–1627 (2008).
  • Kastrati A, Mehilli J, von Beckerath N et al.; ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293(2), 165–171 (2005).
  • Waksman R, Ajani AE, White RL et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 109(3), 340–344 (2004).
  • Alli OO, Teirstein PS, Satler L et al.; SISR Investigators. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. Am. Heart J. 163(3), 438–445 (2012).
  • Alfonso F, Pérez-Vizcayno MJ, Dutary J et al.; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc. Interv. 5(7), 728–737 (2012).
  • Latib A, Mussardo M, Ielasi A et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc. Interv. 4(2), 155–164 (2011).
  • Mehilli J, Byrne RA, Tiroch K et al.; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J. Am. Coll. Cardiol. 55(24), 2710–2716 (2010).
  • Byrne RA, Cassese S, Windisch T et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis: evidence in support of drug resistance. Insights from the ISAR-DESIRE and ISAR-DESIRE 2 Trials. Eurointervention doi:pii:20130124-04 (2013) (Epub ahead of print).
  • Cosgrave J, Melzi G, Corbett S et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am. Heart J. 153(3), 354–359 (2007).
  • Alfonso F, García J, Pérez-Vizcayno MJ et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J. Am. Coll. Cardiol. 54(11), 1036–1038 (2009).
  • Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355(20), 2113–2124 (2006).
  • Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358(7), 689–699 (2008).
  • Indermuehle A, Bahl R, Lansky A et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 99(5), 327–333 (2013).
  • Habara S, Mitsudo K, Kadota K et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc. Interv. 4(2), 149–154 (2011).
  • Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J. Am. Coll. Cardiol. 59(15), 1377–1382 (2012).
  • Byrne RA, Neumann FJ, Mehilli J et al.; ISAR-DESIRE 3 investigators. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381(9865), 461–467 (2013).
  • Indermuehle A, Bahl R, Lansky AJ et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 99(5), 327–333 (2013).
  • Joner M, Radke PW, Byrne RA et al. Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis. J. Biomater. Appl. 27(6), 717–726 (2013).
  • Radke PW, Joner M, Joost A et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention 7(6), 730–737 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.